Consus Real Estate — Largest development platform in Germany

Consus Real Estate (DB: CC1)

Last close As at 04/11/2024

2.28

0.12 (5.31%)

Market capitalisation

368m

More on this equity

Research: Real Estate

Consus Real Estate — Largest development platform in Germany

Consus has solidified its position as the largest residential property developer in Germany with the acquisition of SSN Group (SSN) financed through a combination of cash and equity. The transaction will increase the company’s portfolio to €9.6bn gross development value (GDV), 82% of which is expected to be forward sold. We believe that this transaction constitutes and important step in building a strong, well-diversified portfolio and should lead to favourable synergies given the high business profile overlap between Consus and SSN.

Milosz Papst

Written by

Milosz Papst

Head of Content, Investment Trusts

Real Estate

Consus Real Estate

Largest development platform in Germany

Real estate

Scale research report - Update

20 November 2018

Price

€7.92

<Insert>

Market cap

€849m

<Insert>

Share price graph

Share details

Code

CC1

Listing

Deutsche Börse Scale

Shares in issue

107.2m

Last reported net debt as at 30 June 2018

€1.25bn

Business description

Consus Real Estate, based in Berlin, is the leading, listed residential real estate developer in Germany. Following acquisition of SSN Group, the company's development portfolio consists of 65 projects across nine cities with a gross development value of €9.6bn. It also owns a small commercial assets portfolio.

Bull

Supply shortage in the German residential market.

<Insert text or delete this table row>

Cost-effective and lower-risk business model.

<Insert text or delete this table row>

Extensive development pipeline.

<Insert text or delete this table row>

Bear

Lower selling prices due to forward sale model.

<Insert text or delete this table row>

Bottlenecks in the German residential market.

<Insert text or delete this table row>

Dependency on institutional clients.

<Insert text or delete this table row>

Analysts

Milosz Papst

+44 (0) 20 3077 5700

Michal Mierzwiak

+44 (0) 20 3077 5700

Consus has solidified its position as the largest residential property developer in Germany with the acquisition of SSN Group (SSN) financed through a combination of cash and equity. The transaction will increase the company’s portfolio to €9.6bn gross development value (GDV), 82% of which is expected to be forward sold. We believe that this transaction constitutes an important step in building a strong, well-diversified portfolio and should lead to favourable synergies given the high business profile overlap between Consus and SSN.

Portfolio extended to 65 projects with €9.6bn GDV

On 7 November 2018, Consus announced the acquisition of SSN Group, a residential real estate developer employing a forward sales model similar to Consus’s. As a result, the company’s combined portfolio will now exceed €9.6bn of GDV (vs €6.2bn previously), with 2.1m sqm of total developed area, and the total number of projects will reach 65 (compared to the current 53). The transaction will also provide further geographic diversification of the existing portfolio by enabling Consus to enter the Munich market, which was the last of Germany’s nine largest cities without its presence. The transaction is expected to be completed in Q418.

Financing through cash and equity combination

The price paid for the 93.4% stake in SSN Group of €470m will be funded by a €250m acquisition facility provided by J.P. Morgan. An additional €215m will be paid to Aggregate Group through the issue of 26.9m shares at €8.0 per share, in exchange for 38.9% shares of SG Development and a 43% stake in Project Wilhelm (both SSN subsidiaries). The transaction will put total group indebtedness at €2.2bn (incl. bridge financing) with an average interest rate of 8.1% pa, including SSN debt of €685m at 11.3% pa. Consus is targeting a reduction of debt costs by 2pp as it sees potential to refinance SSN projects at more attractive interest rates.

Upward revision of management guidance

As the company has more than doubled its investment portfolio so far in FY18, management has revised its guidance accordingly, increasing the 2020 EBIT pre-PPA target to €450m (from €300m) at a c 20% EBIT margin. The targeted net debt to EBIT pre-PPA ratio stays at 3.0x (vs 4.4x post-acquisition on Edison estimates), which requires a certain amount of deleveraging initiatives. Management expects no further platform purchases and will focus on acquiring single projects.

Consensus estimates

Year
end

Revenue
(€m)

EBITDA
(€m)

EPS
(€)

DPS
(€)

P/E
(x)

Yield
(%)

12/17

215.0

6.4

0.01

0.0

N/A

N/A

12/18e

716.5

138.0

0.20

0.0

39.6

N/A

12/19e

1,004.3

173.5

0.57

0.0

13.9

N/A

12/20e

1,578.3

277.5

1.21

0.0

6.5

N/A

Source: Consus accounts and Bloomberg consensus as at 9 November 2018

General disclaimer and copyright

This report has been commissioned by Consus Real Estate and prepared and issued by Edison, in consideration of a fee payable by Consus Real Estate. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2018 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd who holds an Australian Financial Services Licence (Number: 427484). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

Neither this document and associated email (together, the "Communication") constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing).

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Neither this Communication nor any copy (physical or electronic) of it may be (i) taken or transmitted into the United States of America, (ii) distributed, directly or indirectly, in the United States of America or to any US person (within the meaning of regulations Regulation S made under the US Securities Act 1933, as amended), (iii) taken or transmitted into or distributed in Canada, Australia, the Republic of Ireland or the Republic of South Africa or to any resident thereof, except in compliance with applicable securities laws, (iv) taken or transmitted into or distributed in Japan or to any resident thereof for the purpose of solicitation or subscription or offer for sale of any securities or in the context where the distribution thereof may be construed as such solicitation or offer, or (v) or taken or transmitted into any EEA state other than the United Kingdom. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this Communication in or into other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts.

More on Consus Real Estate

View All

Latest from the Real Estate sector

View All Real Estate content

ASIT biotech — The 82-centre gp-ASIT+ Phase III study launches

In a well-received announcement, ASIT has launched the confirmatory Phase III study on gp-ASIT+ for grass pollen allergy with study centres in six European countries. The results of the study are expected in December 2019. ASIT has learned from the previous Phase III study by making a number of improvements to the protocol to enhance the chances of success. In addition, ASIT has made announcements on its other products illustrating its pipeline in allergy extends beyond gp-ASIT+.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free